Literature DB >> 8859075

Melanin-laden macrophages in cerebrospinal fluid in Vogt-Koyanagi-Harada syndrome.

S Nakamura1, M Nakazawa, M Yoshioka, I Nagano, H Nakamura, J Onodera, M Tamai.   

Abstract

OBJECTIVE: To identify basophilic granules in the cytoplasm of macrophages in cerebrospinal fluid (CSF) smears from patients with Vogt-Koyanagi-Harada (VKH) syndrome as melanin pigment.
DESIGN: Morphological and immunocytochemical studies were performed on CSF smears obtained from 7 patients with VKH syndrome. Specimens were stained with May-Grünwald and evaluated by a silver impregnation method (Fontana-Masson staining). For immunocyto-chemical study, the smear was reacted with mouse anti-human melanoma cell (HMB-45) monoclonal antibody.
RESULTS: Basophilic granules were detected in the cytoplasm of macrophages in CSF cell smears obtained from 6 of 7 patients with VKH syndrome in the early stages (within 25 days). Using the silver impregnation method, these basophilic granules were strongly stained black. Moreover, they were identified as melanin by positive immunocytochemical staining. The total number of cells containing cytoplasmic granules ranged from 3 to 8 per 10,000 total cells in CSF. In contrast, no cells containing cytoplasmic granules were found in control CSF cell smears from patients with viral, bacterial, or noninflammatory diseases.
CONCLUSION: The identification of melanin-laden macrophages in the CSF of patients with VKH syndrome suggests that these cells are responsible for pleocytosis in the immunopathologic process of VKH syndrome.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8859075     DOI: 10.1001/archopht.1996.01100140384003

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  8 in total

Review 1.  A review of immunologic diseases of the dog.

Authors:  N C Pedersen
Journal:  Vet Immunol Immunopathol       Date:  1999-08-02       Impact factor: 2.046

2.  The spectrum of Vogt-Koyanagi-Harada disease in Tunisia, North Africa.

Authors:  Moncef Khairallah; Sonia Zaouali; Riadh Messaoud; Sami Chaabane; Sonia Attia; Salim Ben Yahia; Kamel Hmidi
Journal:  Int Ophthalmol       Date:  2007-01-04       Impact factor: 2.029

3.  Vogt-Koyanagi-Harada syndrome: A novel case and brief review of focal neurologic presentations.

Authors:  Faheem Sheriff; Nandakumar S Narayanan; Anita J Huttner; Joachim M Baehring
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2014-11-20

Review 4.  Reappraisal of the management of Vogt-Koyanagi-Harada disease: sunset glow fundus is no more a fatality.

Authors:  Carl P Herbort; Ahmed M Abu El Asrar; Joyce H Yamamoto; Carlos E Pavésio; Vishali Gupta; Moncef Khairallah; Ilknur Tugal-Tutkun; Masoud Soheilian; Masuru Takeuchi; Marina Papadia
Journal:  Int Ophthalmol       Date:  2016-11-14       Impact factor: 2.031

5.  Proliferative retinopathy as a feature of Vogt Koyanagi Harada Disease: a report of two cases.

Authors:  Moustafa S Magliyah; Abdulmajeed S Al-Fakhri; Hassan A Al-Dhibi
Journal:  BMC Ophthalmol       Date:  2020-12-01       Impact factor: 2.209

Review 6.  Precise, simplified diagnostic criteria and optimised management of initial-onset Vogt-Koyanagi-Harada disease: an updated review.

Authors:  Carl P Herbort; Ilknur Tugal-Tutkun; Ahmed Abu-El-Asrar; Amod Gupta; Masaru Takeuchi; Christine Fardeau; Alireza Hedayatfar; Cristhian Urzua; Ioannis Papasavvas
Journal:  Eye (Lond)       Date:  2021-06-18       Impact factor: 3.775

7.  Utility of lumbar puncture in diagnosis of Vogt-Koyanagi-Harada disease.

Authors:  Julie H Tsai; Somsiri Sukavatcharin; Narsing A Rao
Journal:  Int Ophthalmol       Date:  2007-03-06       Impact factor: 2.029

8.  Absence of recognition of common melanocytic antigens by T cells isolated from the cerebrospinal fluid of a Vogt-Koyanagi-Harada patient.

Authors:  Sébastien Abad; Grégoire Wieërs; Didier Colau; Claude Wildmann; Emmanuelle Delair; Robin Dhote; Antoine P Brézin; Yukata Kawakami; Pierre G Coulie; Pierre van der Bruggen
Journal:  Mol Vis       Date:  2014-07-02       Impact factor: 2.367

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.